Table 3 Treatments and clinical outcomes of the patients with Chlamydia psittaci or COVID-19.

From: Comparison of clinical, laboratory and radiological characteristics between COVID-19 and Chlamydia psittaci pneumonia: a multicenter retrospective study

Variable

Total (n = 531)

Chlamydia psittaci (n = 81)

COVID-19 (n = 450)

p Value

Respiratory support mode

    

No need for respiratory support

2(0.4)

1(1.2)

1(0.2)

 < 0.01

Conventional oxygen, n (%)

416 (78.3)

34 (42.0)

382 (84.9)

 < 0.001

High-flow nasal cannula, n (%)

30 (5.7)

18 (22.2)

12 (2.7)

 < 0.001

Non-invasive ventilation, n (%)

15 (2.8)

2 (2.5)

13 (2.9)

1.000

Invasive ventilation, n (%)

68 (12.8)

26 (32.1)

42 (9.3)

 < 0.001

Other treatments

    

Glucocorticoid, n (%)

180 (34.1)

14 (17.3)

167 (37.1)

0.001

Immunoglobulin, n (%)

111 (20.9)

2 (2.5)

109 (24.2)

 < 0.001

Vasopressor, n (%)

50 (9.4)

16 (19.8)

34 (7.6)

0.001

CRRT, n (%)

14 (2.6)

4 (4.9)

10 (2.2)

0.304

Clinical outcomes

    

ARDS, n (%)

68 (12.8)

26 (32.1)

42 (9.3)

 < 0.001

Severe pneumonia, n (%)

218 (41.1)

45 (55.6)

173 (38.4)

0.004

Septic shock, n (%)

55 (10.4)

19 (23.5)

36 (8.0)

 < 0.001

30 days mortality, n (%)

26 (4.9)

8 (9.9)

18 (4.0)

0.048

ICU admission, n (%)

87 (16.4)

48 (59.3)

39 (8.7)

 < 0.001

Length of hospital stay of survivors, days

30.0 (20.0, 38.0)

10.0 (8.0, 18.0)

31.0 (22.0, 40.0)

 < 0.001

  1. Data are presented as medians (IQR) and n (%). P values were calculated by Mann–Whitney U test, Chi-square test or Fisher’s exact test, as appropriate. p values indicate differences between Chlamydia psittaci group and COVID-19 group. Abbreviations: ARDS, Acute respiratory distress syndrome; ICU, intensive care unit; Continuous renal replacement therapy, CRRT.
Back to article page